INDBInternet News Database 2.5 Updated 1 min ago · 297 sources Show or hide images Light or dark

Akeso shares plummet as Chinese firm’s cancer drug ivonescimab faces FDA setback

Save Like Comments Compare coverage
Image from South China Morning Post

Summary

Shares in Hong Kong-listed Akeso plunged as much as 31.8 per cent on Monday morning after the US Food and Drug Administration (FDA) rejected its cancer drug application, raising investor worries over the company’s near-term commercial outlook. Ivonescimab, one of the most closely watched innovative drugs emerging from China, did not establish “substantial evidence of effectiveness”, said US firm Summit Therapeutics, which has the exclusive rights to develop and commercialise the drug in global...

Description from South China Morning Post.

Who is covering this

  1. South China Morning Post Leans right Factuality: High HK
    Akeso shares plummet as Chinese firm’s cancer drug ivonescimab faces FDA setback

    Shares in Hong Kong-listed Akeso plunged as much as 31.8 per cent on Monday morning after the US Food and Drug Administration (FDA) rejected its cancer drug application, raising investor worries over the company’s near-term commercial outlook. Ivonescimab, one of the most...

Comments

Comments need JavaScript.